Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $84,644.84 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 4,207 shares of Travere Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $84,644.84. Following the completion of the transaction, the insider now directly owns 85,236 shares of the company’s stock, valued at $1,714,948.32. This trade represents a 4.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.76, for a total transaction of $8,254.40.
• On Friday, January 3rd, Jula Inrig sold 2,066 shares of Travere Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $39,460.60.

Travere Therapeutics Stock Up 3.1 %

Shares of NASDAQ TVTX opened at $21.86 on Friday. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $22.13. The stock has a fifty day moving average price of $18.80 and a two-hundred day moving average price of $15.56. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Wall Street Analysts Forecast Growth

TVTX has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. HC Wainwright upped their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Scotiabank increased their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Barclays boosted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $9.00 to $27.00 in a research note on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Institutional Trading of Travere Therapeutics

Several institutional investors have recently modified their holdings of the company. Arizona State Retirement System grew its holdings in Travere Therapeutics by 13.5% during the fourth quarter. Arizona State Retirement System now owns 22,396 shares of the company’s stock worth $390,000 after acquiring an additional 2,666 shares during the period. Aigen Investment Management LP boosted its position in shares of Travere Therapeutics by 56.6% during the 4th quarter. Aigen Investment Management LP now owns 19,072 shares of the company’s stock valued at $332,000 after purchasing an additional 6,892 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Travere Therapeutics in the 4th quarter worth approximately $182,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Travere Therapeutics by 16.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 661,603 shares of the company’s stock worth $11,525,000 after purchasing an additional 94,194 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Travere Therapeutics by 323.4% during the fourth quarter. US Bancorp DE now owns 31,795 shares of the company’s stock valued at $554,000 after purchasing an additional 24,286 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.